Heron Therapeutics (HRTX) Stock: Buy, Sell, or Hold?
HRTX - Heron Therapeutics, Inc.
$0.32
-0.01 (-2.11%)
âŧ
5d:
-4.39%
30d:
-7.45%
90d:
-22.27%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When HRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HRTX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HRTX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: HRTX is currently trading at $0.32, which is considered slightly low relative to its 30-day fair value range of $0.29 to $0.42. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.9) compared to its historical average (1.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HRTX is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.35.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.00 (+2118.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HRTX is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.35.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.00 (+2118.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.29 -
$0.42
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 2118.7% below Wall St target ($7.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.29 -
$0.42
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.30
Resistance Level
$0.36
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.87
Wall Street Target
$7.00
(+2118.7%)
Revenue Growth (YoY)
1.3%
Profit Margin
-22.5%
PE vs Historical
-2.9 vs 1.9
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 3:40 PM ET
Data refreshes hourly during market hours. Next update: 4:40 PM
Data refreshes hourly during market hours. Next update: 4:40 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$137 | 47 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
